Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 272 resultater
Tid
Selskap
Tittel
Sektor
Kategori
10 Dec 2024
22:30 CET
CELLECTIS
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
20103010 Biotechnology
-
10 Dec 2024
22:30 CET
CELLECTIS
Cellectis annonce le tirage de la troisième tranche de 5 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Européenne d’Investissement (BEI)
20103010 Biotechnology
-
04 Dec 2024
22:30 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
04 Dec 2024
22:30 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
06 Nov 2024
22:38 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
06 Nov 2024
22:38 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
05 Nov 2024
22:30 CET
CELLECTIS
Cellectis présente de multiples stratégies pour améliorer l'efficacité des cellules CAR T dans les tumeurs solides à la réunion annuelle de la SITC
20103010 Biotechnology
-
05 Nov 2024
22:30 CET
CELLECTIS
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
20103010 Biotechnology
-
04 Nov 2024
22:30 CET
CELLECTIS
Cellectis présente ses résultats financiers du troisième trimestre 2024 et une mise à jour de ses activités
20103010 Biotechnology
-
04 Nov 2024
22:30 CET
CELLECTIS
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
20103010 Biotechnology
-
30 Oct 2024
21:30 CET
CELLECTIS
Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024
20103010 Biotechnology
-
30 Oct 2024
21:30 CET
CELLECTIS
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
20103010 Biotechnology
-
22 Oct 2024
08:00 CEST
CELLECTIS
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
20103010 Biotechnology
-
22 Oct 2024
08:00 CEST
CELLECTIS
Cellectis présentera des données sur des TALE Base Editors ainsi que sur son programme de thérapie génique non-virale lors du 31ème congrès annuel de l’ESGCT
20103010 Biotechnology
-
02 Oct 2024
22:30 CEST
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
02 Oct 2024
22:30 CEST
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
04 Sep 2024
22:30 CEST
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
04 Sep 2024
22:30 CEST
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
03 Sep 2024
22:30 CEST
CELLECTIS
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
20103010 Biotechnology
-
03 Sep 2024
22:30 CEST
CELLECTIS
Cellectis présente des preuves précliniques de l’efficacité des cellules CAR T MUC1 contre le cancer du sein triple négatif tout en préservant la sécurité
20103010 Biotechnology
-
26 Aug 2024
22:30 CEST
CELLECTIS
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
20103010 Biotechnology
-
26 Aug 2024
22:30 CEST
CELLECTIS
Cellectis publie un article dans Molecular Therapy sur la conception de cellules CAR T pour le traitement de tumeurs solides récalcitrantes
20103010 Biotechnology
-
07 Aug 2024
08:00 CEST
CELLECTIS
Cellectis nomme le docteur Adrian Kilcoyne directeur médical
20103010 Biotechnology
-
07 Aug 2024
08:00 CEST
CELLECTIS
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
20103010 Biotechnology
-
06 Aug 2024
22:30 CEST
CELLECTIS
Cellectis Provides Financial Results for the Second Quarter 2024
20103010 Biotechnology
-
06 Aug 2024
22:30 CEST
CELLECTIS
Cellectis publie ses résultats financiers du deuxième trimestre 2024
20103010 Biotechnology
-
05 Aug 2024
22:30 CEST
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
05 Aug 2024
22:30 CEST
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
01 Aug 2024
22:30 CEST
CELLECTIS
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
20103010 Biotechnology
-
01 Aug 2024
22:30 CEST
CELLECTIS
La FDA accorde le statut de médicament orphelin à CLLS52 (alemtuzumab) de Cellectis pour le traitement de la LLA
20103010 Biotechnology
-
25 Jul 2024
22:30 CEST
CELLECTIS
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
20103010 Biotechnology
-
25 Jul 2024
22:30 CEST
CELLECTIS
La FDA accorde le statut de médicament orphelin et médicament pour une maladie pédiatrique rare (Rare Pediatric Disease Designation-RPDD) au produit candidat de Cellectis UCART22 pour le traitement de la leucémie lymphoblastique aiguë (LLA)
20103010 Biotechnology
-
05 Jul 2024
22:30 CEST
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
05 Jul 2024
22:30 CEST
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
28 Jun 2024
22:30 CEST
CELLECTIS
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
20103010 Biotechnology
-
28 Jun 2024
22:30 CEST
CELLECTIS
Résultats de l’Assemblée Générale Mixte de Cellectis du 28 juin 2024
20103010 Biotechnology
-
20 Jun 2024
22:30 CEST
CELLECTIS
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
20103010 Biotechnology
-
20 Jun 2024
22:30 CEST
CELLECTIS
Cellectis publie un article scientifique dévoilant trois facteurs clés pour une édition efficace avec des TALE base editors
20103010 Biotechnology
-
12 Jun 2024
22:30 CEST
CELLECTIS
Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications
20103010 Biotechnology
-
12 Jun 2024
22:30 CEST
CELLECTIS
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
20103010 Biotechnology
-
05 Jun 2024
22:30 CEST
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
05 Jun 2024
22:30 CEST
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
04 Jun 2024
22:30 CEST
CELLECTIS
Cellectis obtient la désignation de médicament orphelin pour son produit CAR T allogénique UCART22 pour les patients atteints de leucémie lymphoblastique aiguë
20103010 Biotechnology
-
04 Jun 2024
22:30 CEST
CELLECTIS
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
20103010 Biotechnology
-
29 May 2024
22:30 CEST
CELLECTIS
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
20103010 Biotechnology
-
29 May 2024
22:30 CEST
CELLECTIS
L’ Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2024
20103010 Biotechnology
-
28 May 2024
22:30 CEST
CELLECTIS
Cellectis publie ses résultats financiers du premier trimestre 2024
20103010 Biotechnology
-
28 May 2024
22:30 CEST
CELLECTIS
Cellectis Reports Financial Results for First Quarter 2024
20103010 Biotechnology
-
27 May 2024
22:30 CEST
CELLECTIS
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
20103010 Biotechnology
-
27 May 2024
22:30 CEST
CELLECTIS
Cellectis publiera ses résultats financiers du premier trimestre 2024 le 28 mai 2024
20103010 Biotechnology
-
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
DSP
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva